Drug Assessment for Hypertension Treatment

1466 Words6 Pages
Introduction Hypertension is one of the most important health issue. It is one of the leading cause for heart disease, stroke and kidney disease. (Gay & Ndefo 2008). Anti-hypertensive drugs include several classes of medications which are used to control blood pressure in hypertensive patients. β-blockers are one of these classes which are widely prescribed worldwide. Because of the tolerability issue, the uses of β-blockers have been limited and are no longer considered as a first-line treatment for hypertension. Nebivolol , a new β-blocker, possesses different pharmacological properties from traditional β-blockers. Due to its superior anti-hypertensive efficacy and excellent safety profile, Nebivolol may be used as a first-line…show more content…
The second mechanism involves the production of Nitric Oxide via L-arginine/nitric oxide pathway which is responsible for its vasodilatory activity (Cheng 2009 and Moen and Wagstaff 2006). This dual action belongs to the fact that its racemic mixture consists of l and d isomers. The vasodilating effect belongs to the l- isomer and the latter possesses β1-blocking activity (Gray & Ndefo 2008 and Moen &Wagstaff 2006).The efficacy of Nebivolol as anti-hypertensive drug was evaluated by Van Borteletal. inGray & Ndefo( 2008) who compared the anti-hypertensive effect of Nebivolol in a dose of 5mg/day with placebo. After a period of 4 weeks, there was a reduction in blood pressure of at least 10 mm Hg in 65% of patients treated with Nebivolol compared to 25% with placebo.The ability of Nebivolol to increase Nitric Oxide bioavailablity has an obvious impact ton reducing systemic vascular resistance which leads to a further decrease in blood pressure and it will also reduce the incidence of cardiovascular diseases caused by endothelial dysfunction which is a common disorder in patients with hypertension and diabetes and usually results from a decrease in nitric oxide bioavailability (Moen & wagstaff, 2006).The ability of Nebivolol to inhibit platelet aggregation has been showed by Munzel &Gori(2009) who claimed that Nebivolol
Open Document